Key points
- Global Sales Revenue: $7.7m, up 6%
- Australian Sales Revenue: $5.8m, up 10%
- FDA approval for IMM-529 IND
- Net Profit improvement: $(3.8)m, up $1.4m
- Cash improvement: $9.0m, up $6.2m
Full summary
Immuron Ltd's FY26 results showed global sales revenue of $7.7 million, a 6% increase. Australian sales rose 10% to $5.8 million, and U.S. sales increased by 7% to $1.8 million. The company received FDA approval for IMM-529 IND, completed the Travelan® n=851 trial, and launched a new product in Australia. Net profit improved by $1.4 million to $(3.8) million, and cash reserves increased to $9.0 million. The company also engaged Pullan Consulting to support partnering for IMM-529 and initiated a strategic reset aimed at profitability and reduced cash burn.
Guidance
Global Sales Revenue: $7.7m, Australian Sales Revenue: $5.8m, Net Profit: $(3.8)m, Cash: $9.0m
Outlook
Immuron Ltd expects continued Travelan® sales growth, portfolio expansion, geographic sales expansion, and partnering update for IMM-529. The company aims for improved profitability and reduced cash burn through FY27-FY28.